Key Takeaways
- • Estuary Biotherapeutics launched with $103 million in total committed financing, including a $93 million Series A led by RA Capital Management.
- • The Series A drew participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, and a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD).
- • 4BIO Capital and GV, which co-led the company's $10 million seed round, also participated in the Series A.
- • Estuary is developing genetic medicines for patients with serious kidney diseases, based in Menlo Park, California.
Summary
Estuary Biotherapeutics, a biotechnology company developing genetic medicines for patients with serious kidney diseases, announced its launch with $103 million in total committed financing, according to the company's announcement. The package consists of a $93 million Series A round and the earlier $10 million seed financing.
The Series A was led by RA Capital Management. Participants included Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, and a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD). Seed co-leads 4BIO Capital and GV also joined the Series A.
The mix of specialist life-sciences investors, a corporate venture arm, a patient-advocacy foundation fund, and a family office with a direct ADPKD connection reflects the company's focus on hereditary kidney disease. The company is based in Menlo Park, California.
The Series A was led by RA Capital Management. Participants included Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, and a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD). Seed co-leads 4BIO Capital and GV also joined the Series A.
The mix of specialist life-sciences investors, a corporate venture arm, a patient-advocacy foundation fund, and a family office with a direct ADPKD connection reflects the company's focus on hereditary kidney disease. The company is based in Menlo Park, California.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.